Respiratory syncytial virus (RSV) accounts for about 20% of all respiratory infections in children below the age of 5 y. It is associated with up to 63% of all acute respiratory infections and up to 81% of all viral lower respiratory tract infections causing hospitalization in infants and young children. RSV leads to seasonal epidemics between November and April in the northern hemisphere. Most severe infections (RSV accounts for 50 to 80% of all cause bronchiolitis) affect infants younger than 6 months of age and highrisk infants including those born preterm with or without bronchopulmonary dysplasia and those with hemodynamically significant congenital heart disease up to an age of 24 months. Palivizumab, a highly potent RSV-neutralizing monoclonal antibody (Mab), has been licensed in 1998 for prophylactic use to prevent RSV associated hospitalizations in high-risk infants. This Mab is given by monthly intramuscular injection at a dose of 15 mg/kg over the RSV season (up to 5 times). Palivizumab proved to be safe and well-tolerated in this population. Concerns have been raised regarding cost-effectiveness of palivizumab and thus, palivizumab prophylaxis is mainly limited to selected high-risk infants for the first RSV season. Long-lasting Mabs will be the next future approach in the prophylaxis of RSV hospitalization until a vaccine is developed.
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Respiratory syncytial virus
In 1955 a new virus was isolated from chimpanzees with symptoms of an upper respiratory tract infection including coughing and sneezing with mucopurulent nasal discharge called chimpanzee coryza agent (CCA). Chanock and colleagues confirmed its human origin when they isolated the virus from an infant with bronchopneumonia and another with laryngotracheobronchitis. Due to its ability to form syncytia in human liver epithelial cell lines the virus was renamed respiratory syncytial virus (RSV), and it was first isolated during a bronchiolitis epidemic in 1960. 1, 2 RSV is a member of the Paramyxoviridae family. It is a medium-sized (120-200 nm) enveloped virus containing a lipoprotein coat and a linear negative-sense RNA genome of 10 genes encoding 11 proteins (completely sequenced since 1997). 3 Two serotypes are known -group A and B -and type A is considered to be the more virulent strain. RSV has 2 major proteins: the F-glycoprotein for fusion and G-glycoprotein for attachment to the host cells. These are the major targets for neutralizing antibodies. The F-glycoprotein is more conserved among strains and by 95% identical between serotypes A and B. 4 There is a 40-to 90-fold increase in F-specific compared with a 5-to 20-fold increase in G-specific antibody titer after primary infection. 5 Interestingly, severity of disease seems to be unrelated to RSV-specific IgG antibody titers, avidity of RSVIgG or virus neutralization capacity. 6 RSV infects the bronchial, bronchiolar and alveolar epithelium, and also the airway dendritic cells. The virus is recognized by different pattern recognition receptors (PRRs) which trigger the innate immune response. T cell immunity is mandatory for virus clearance. This T helper (Th)-2 and Th-17 T cell response results in the recruitment of T cells, neutrophils and eosinophils with subsequent inflammation and tissue damage of the lung. 7, 8 Both CD4C and CD8C T cells have been demonstrated to be essential for the establishment of an efficient RSV immunity, and these immune reactions are both beneficial and detrimental for the host. Approximately one third of the children can exhibit reinfection during one winter. 8 These reinfections are supposed to be the result of deficiencies of the humoral and cellular immune response after the first RSV infection. Disease severity has been associated with high viral loads, but in contrast low viral loads have been observed in severe disease in case of prematurity. 9 Respiratory syncytial virus and burden of disease Most children are infected during the first 2 y of life, and nearly all have been infected after the second RSV season. Despite limited antigenic variation RSV immunity is short and recurrent infections occur life-long with the first episode during the first season being the most severe one. 4, 9 One to 3% of all healthy term infants exhibit hospitalization due to RSV associated lower respiratory tract infection (LRTI) due to primary RSV infection mainly during the first 6 months of life. This rate increases up to about 10% in high risk populations including preterm infants with and without bronchopulmonary dysplasia, infants with hemodynamically significant congenital heart disease, Down syndrome, neuromuscular disease and severe immune deficiency syndrome or immunosuppression. 9, 10 RSV is a seasonal virus with infection rates peaking during the cold season in temperate s and rainy seasons in tropical climates. Typically, RSV related hospitalizations occur between November and April in the northern hemisphere and most often peak in January and February. 11, 12 Sometimes a severe RSV season is followed by a less severe season, and an early peaking season is followed by a late peaking one, but RSV activity has also been (rarely) observed through the whole year -as data from Austria have shown. 12 RSV is mainly transmitted by large particle aerosols or direct contact. Incubation time is 4-5 d with initial viral replication in the nasopharynx; thereafter the virus can spread and cause lower LRTI. Thus, RSV infection ranges from that of a mild common cold to bronchiolitis with airway obstruction, hypoxia, and wheezing, or pneumonia. 13 Upper respiratory tract infections (URTI) characterized by rhinitis, cough, and mostly mild fever reaction are the most common manifestations of RSV. Acute otitis media -up to 20-30% -and less often croup have been reported to occur in children with RSV illness, and bronchiolitis and pneumonia are the more common features of RSV disease in infants and young children -mostly as the first episode of an RSV infection. 4 RSV is responsible for 50 to 80% of all hospitalizations for bronchiolitis during seasonal epidemics.
14 RSV was found to be associated with 12 to 63% of all acute respiratory infections (resulting in 1 of 334 hospitalizations, 1 of 38 admissions to the emergency department, and 1 of 13 admissions to the primary care office per year in the USA) and 19 to 81% of all viral LRTIs causing hospitalization in children. 15 RSV hospitalization rates increase with decreasing age and vary by a factor of 2 to 3 dependent on severity of the RSV season. The length of hospital stay ranges from median 2 to 11 d in high-risk populations, with 2 to 12% of cases requiring intensive care unit (ICU) admission throughout the studies. 15 Risk factors associated with RSV hospitalization include male sex, young age below 6 months, birth during the first half of the RSV season, crowding and/or presence of siblings, and day-care exposure. 4, 10, 15 Bronchiolitis-associated deaths have been reported to be 2.0 per 100 000 livebirths from the late 1990s; 16 and case-fatality rates were reported to be below 0.5% -retrieved from studies published between 1995 and 2015. 15 About 34 million new cases of RSV associated LRTI globally occur in children younger than 5 years; with 3.4 million hospital admissions and about 199,000 deaths per year(predominantly in developing countries). In developed countries such as the USA, bronchiolitis is the most common reason for hospital admission up to the age of 12 months accounting for about 100,000 infant admissions annually. 16, 17 In a prospective surveillance study including children up to the age of 5 y with acute respiratory infections from the USA 18% (919 of 5067 infants) had diagnosis of RSV U/LRTI. 18 RSV was found in 20% of all hospitalizations due to acute respiratory infection, in 18% of the emergency department admissions, and in 15% of the primary care office admissions between the months November and April. These findings resulted in annual hospitalization rates of 17 per 1000 infants up to the age of 6 months and 3 per 1000 children up to the age of 5 y. 18 The incidence of RSV associated apneas is reported to range from 1.2 to 23.8% with higher rates in preterm infants. 19 Encephalitis/encephalopathy is a rare but well described complication of RSV infection, predominantly manifesting as ataxia. 20 Severe RSV bronchiolitis during early infancy is often associated with subsequent episodes of wheezing which can persist until adolescent age. 21 
Treatment and prevention of RSV bronchiolitis

Symptomatic treatment
The treatment of RSV bronchiolitis is primarily symptomatic and includes oral or parenteral fluid replacement to maintain adequate hydration, supplemental oxygen in case of desaturation (SpO2 below 92%), and decongestant nose drops. 22 In case of acute respiratory failure transfer to the ICU and noninvasive ventilator support via CPAP or invasive mechanical ventilation has to be considered. Extracorporeal membrane oxygenation (ECMO) is a lifesaving option for a minority of cases, mostly with diagnosis of prematurity and bronchopulmonary dysplasia. 23 Bronchodilators including salbutamol, albuterol, epinephrine or heliox might have at least short-term benefits for the patients, as it is also the case for aerosolized hypertonic saline. The use of inhaled or systemic corticosteroids and leukotriene antagonists, both as anti-inflammatory agents, showed lack of benefits. 22, 24 The only FDA-approved antiviral drug against RSV is ribavirin. There are a lot of controversies and concerns around its efficacy, tolerability, and the route of administration. Thus, ribavirin is not recommended for routine use in the treatment of RSV disease but might be considered in life-threatening infections and in immunocompromised hosts with severe disease. 22, 25 Preventive strategies
In the early 1960s, vaccination of infants with a formalin-inactivated RSV vaccine resulted in a significant increase of neutralizing antibodies but led to the death of 2 infants resulting from a vaccine-enhanced disease during the following RSV season. 26 Reasons for the difficulties developing a vaccine include the necessity of vaccination in the presence of maternal antibodies, the phenomenon of recurrent reinfections following wild virus infection, and the lack of adequate animal models completely reproducing human RSV infection.
Vaccine development is ongoing based on different approaches as shown in Fig. 1 . Details are beyond this product review.
Standard polyclonal immunoglobulin preparations were neither successful in the prevention of RSV hospitalisation nor in the treatment of RSV disease. 27, 28 In contrast, an RSV enriched hyperimmmune globulin (RSV-IGIV, RespiGam Ò ) that was given parenteral at doses of 750 mg/kg monthly (5 times) during the RSV season was safe and effectively reduced RSV hospitalization rates in preterm infants with and without bronchopulmonary dysplasia and infants with cyanotic congenital heart disease. 29, 30 Unfortunately the latter more often experienced serious adverse events including sudden unexplained death following cardiac surgery. 31 Thus, the American Academy of Pediatrics (AAP) recommended RSV-IGIV only for preterm infants with or without a history of bronchopulmonary dysplasia and excluded those with congenital heart disease. 32 RSV-IGIV had the disadvantage of monthly time-consuming infusions and the minimal risk of blood-borne pathogen transmission. 33 Some years following license of palivizumab it was taken from the market.
Origin and research basis for the design of palivizumab
The development of a monoclonal antibody (Mab) that neutralizes RSV was the next step in the development of a simpler administrable and maybe more effective RSV immune prophylaxis tool. Shortly, 18 neutralizing Mabs specific for the F-glycoprotein were used to construct a detailed map of epitopes that were involved in virus neutralization and fusion. 34 Competitive binding assays identified further antigenic and bridge sites. Following selection of Mab-resistant mutants to identify additional epitopes cross-neutralization assays were used for examination of antigenic variation in the F epitopes. This resulted in the identification of constant, variable, and hypervariable regions. 34 Palivizumab (Synagis Ò ), a monoclonal antibody to the RSV F-protein, was developed over a 10-year period by MedImmune Inc. (Gaithersburg, MD) for prophylactic use against RSV disease.
35 The F-protein was selected as the antibody target to enable both the A and B subtype strains to be neutralized. There are 2 effects by antibody binding to the F-protein. The one is that it hampers the viral to fuse with the cell membrane; the second is that it avoids the formation of syncytia in the lung by preventing cell-to-cell spread of the virus. 35 In detail, antibody production was initiated following immunization of a mouse with RSV. Thereafter the antibody producing B cells were isolated from the mouse spleen and fused with mouse myeloma cell lines -with the advantage of indefinite living (hybridoma cell line) -that produced the antibody accordingly. The mouse monoclonal antibody was humanized by cloning and sequencing the DNA from both the heavy and light chains of the Mab. Following identification of the complementarity-determining-region-sequences they were molecularly "transplanted" into human immunoglobulin genes by use of computer modeling of the required 3-dimensional structures of both variable regions. Thus, the Mab is by 95% comparable to any other human antibody, and only 5% of its DNA origins from the mouse. Thereafter the genes were inserted into a plasmid expressed from Escherichia coli bacteria and then inserted into the hybridoma cell line by electroporation. This method uses an electric shock application of about 1500 V to opens up holes in the membrane, which allows entrance of the plasmid DNA and integration into the chromosome. This procedure initiated the production of the humanized antibody by the cells. Palivizumab was the first humanized monoclonal antibody ever shown to be effective against an infectious disease. 
Pharmacokinetics and -dynamics
The affinity of palivizumab was slightly better than a chimeric derivative of the parent antibody, and palivizumab was found to be more potent than RSV-IGIV. 36 Palivizumab neutralized a broad panel of 57 RSV isolates including both subtypes A and B. At a dose of 2.5 mg/kg prophylactic palivizumab treatment of cotton rats resulted in a 99% reduction of RSV titers in their lungs. Corresponding serum concentrations were at 25 to 30 mg/mL. Furthermore, palivizumab demonstrated no induction of increased RSV pathology by primary or secondary challenge. 36 To answer the question for a possible presence of palivizumab-resistant mutants, an immunofluorescence binding assay was investigated to test neutralization of RSV isolates from 458 infants hospitalized for RSV LRTI between 1998 and 2002. 37 Palivizumab effectively bound to all 371 evaluated RSV isolates; 25 derived from palivizumab recipients. In comparison to another RSV Mab called felvizumab and to RSV-IGIV palivizumab was better neutralizing RSV by 5 and 20 times, respectively. 38 The concentrations necessary for a 50% inhibition of RSV were 0.23 mg/mL for palivizumab, 0.95 mg/mL for felvizumab, and 9.26 mg/mL for RSV-IGIV. 38 Interestingly, an 8.7% prevalence of resistance mutations at the F-glycoproteins 23 amino acid sequences has been observed in a small cohort of palivizumab recipients that might have an impact on palivizumab efficacy over the years. 39 Palivizumab was twice as potent as RSV-IGIV in reducing capsaicin-induced neurogenic extravasation in the airways following RSV infection when given before intranasal inoculation, and, in contrast to RSV-IVIG, also caused significant RSV inhibition following endotracheal inoculation in Fisher rats. 40 Furthermore, palivizumab inhibited neurogenic inflammation even when given 3 d following RSV inoculation. These findings suggested efficacy of palivizumab in the protection of inflammation of the respiratory tract by RSV.
Efficacy of palivizumab on reducing RSV loads has been proven in either nasal 41 or tracheal aspirates 42 of preterm infants below 2 y of age. Nasal aspirates from 27 hospitalized preterm infants with RSV infection who had not received palivizumab were prospectively compared with 10 infants having received palivizumab regarding RSV loads. 41 Mean nasal RSV loads in both groups were 3.36 and 4.89 logPFU/ml, respectively, demonstrating a significant reduction of nasal RSV loads (p D 0.01). The effect of palivizumab on tracheal RSV concentrations was shown in 35 children mechanically ventilated for RSV infection (below 2 y of age). 42 RSV concentrations, measured before treatment and at daily intervals after treatment, were significantly reduced from day 0 to day 1 and from day 0 to day 2 (p D 0.004 and 0.012, respectively). Nasal RSV concentrations were not different between groups.
Transient, low level anti-palivizumab binding antibodies with titers ranging from 1:10 to 1:40 were detected in 10 of 65 preterm infants (15%) in a multicenter dose finding trial. 43 There was one child showing a transient anti-idiotypic antibody response (1:10) and another with asymptomatic elevation of AST and non-measurable palivizumab concentrations 30 d following the last palivizumab dosage.
In summary these preclinical studies revealed broad neutralizing activity of palivizumab against RSV including both A and B subtypes that exceeded that of RSV-IGIV by 50 to 100 times.
The pharmacokinetic properties of palivizumab were studied in high-risk infants up to the age of 2 y. Following intramuscular injection palivizumab is slowly absorbed and maximum serum concentrations are reached at 3 to 5 d. 44 Two days after the first and second intramuscular injection of palivizumab of 15 mg/kg Mean serum concentrations were 91.1 and 150.3 mg/mL, respectively, following the first and second palivizumab administration. 43 Cardiopulmonary bypass reduced mean serum palivizumab concentrations by 58%. 45 The mean distribution volume of palivizumab was found to be 57 mL/kg. 44 Trough serum palivizumab concentrations were below a C min 40 mg/ml at dose intervals of 28 to 30 d following dose 1 in 29 -68%, dose 2 in 0 -14%, dose 3 in 0 -9%, dose 4 in 0 -4%, and following dose 5 in 0 -5%. 46 Following intravenous as intramuscular palivizumab injection mean serum elimination half-life was reported to differ between19.3 and 26.8 d. 47 
Clinical studies
Phase I/II Between 1 and 5 monthly injections were given at doses of 5 mg/kg (n D 11), 10 mg/kg (n D 6) and 15 mg/kg (n D 48), respectively, in 65 high-risk children. 43 Mean serum palivizumab concentrations (enzyme-linked immunosorbent assay) were 91.1 (range 52.3 -174.0) mg/mL 2 d after the initial dose of 15 mg/kg and 49.2 (range 13.5 -132.0) mg/mL at 30 d. Monthly injections of 15 mg/kg revealed mean trough serum concentrations of 70 mg/mL. Injections were generally well-tolerated. Adverse effects possibly being related to palivizumab were observed in 3 children (3.4%). Two patients in the 5-mg/kg dose group were hospitalized for RSV; and no RSV hospitalizations were found in the higher dose groups. 43 In another trial high-risk infants were randomized to receive 3, 10 or 15 mg/kg palivizumab intravenously compared with placebo (0.9% saline) each month for up to 5 administrations. 47 Palivizumab was safe and well-tolerated and did not induce a specific anti-palivizumab response. The mean half-life of 20 d compared well to other IgG preparations. Mean trough serum concentrations were 6.8, 36.1 and 60.6 mg/ml for the 3-, 10-and 15-mg/kg dose groups, respectively, 30 d following the first infusion and 11.9, 45.2 and 70.7 mg/mL, respectively, following the second Infusion. Thereafter, mean trough serum concentrations ranged from 14 to 18 mg/mL in the infants given 3 mg/kg palivizumab, from 46 to 72 mg/mL in those given 10 mg/kg, and from 88 to 96 mg/mL for those given 15 mg/kg. 47 
Phase III/IV
Over the RSV season 1996/97, 1502 preterm infants with or without bronchopulmonary dysplasia received 5 injections of either palivizumab (15 mg/kg) or placebo by intramuscular injection monthly for up to 5 administrations. 48 Infants were recruited from 139 centers in the USA, UK and Canada. The placebo and palivizumab groups did not differ regarding demographic data and presence of typical RSV risk factors, and compliance was high (99% completed the study). Palivizumab prophylaxis resulted in an overall 55% reduction in RSV related hospitalizations (10.6% vs 4.8%). Infants without bronchopulmonary dysplasia showed a 78% reduction (8.1% vs 1.8%), those with bronchopulmonary dysplasia a 39% reduction (12.8% vs 7.9%), infants below 32 weeks a 47% and infants between 32 and 35 weeks of gestational age an 80% reduction. Thus, the infants having the most severe underlying morbidity only showed a modest reduction in RSV hospitalization. Further analyses exhibited fewer total RSV hospital days (36.4 vs. 62.6/100 children), fewer days with supplemental oxygen (30.3 vs. 50.6/100 children), fewer days with a moderate/severe LRTI (29.6 vs. 47.4/100 children), and a lower incidence of PICU admission rate (1.3 vs, 3.0%). Mean trough serum concentrations 30 d following injection number 1, 2, 3 and 4 were 37, 57, 68 and 72 mg/mL, respectively. There were no differences regarding adverse events between groups, and only 0.3% discontinued before completion. Injection site reactions occurred in 1.8% in the placebo compared with 2.7% in the palivizumab group. Frequent observations included erythemas and elevations of AST and ALT. 48 In 1287 children with congenital heart disease palivizumab prophylaxis given over 4 seasons (1998 -2002) resulted in a 45% relative reduction of RSV hospitalizations. 49 Additionally significant findings included a 56% reduction in hospitalization days per 100 children (9.7% placebo vs 5.3%), and a 73% reduction in days with need for supplemental oxygen per 100 children (p D 0.014). There were similar rates of adverse events observed and no serious adverse events found being related to palivizumab. Deaths occurred in 3.3% in the palivizumab and 4.2% in the placebo group and none was related to palivizumab. No adverse events were recorded in regard to cardiac surgery, thus, compared with RSV-IGIV monthly palivizumab injections were safe, well-tolerated, and effective in preventing RSV disease requiring hospitalization in this population. 49 The Expanded Access Study included 565 infants from 80 centers in 15 countries of the Northern Hemisphere over the 1998/99 RSV season. 50 The rate of adverse events was low (6.9%) including injection site reaction, fever, diarrhea, and irritability. Serious adverse events included hospitalization and one case of RSV bronchiolitis not requiring hospitalization. The RSV hospitalization rate was calculated with 2.1% (12/565) -not all cases were tested for RSV. 50 A total of 285 preterm infants of 29 to 32 weeks of gestational age without bronchopulmonary disease and age below 6 months was enrolled from 35 centers out of 18 countries over the 2000/2001 RSV season (PROTECT study). 51 More than half of the infants (56%) were below 12 weeks of age at study entry, and more than 80% of infants received minimum 4 palivizumab injections. Adverse events (> 5%) were observed including rhinitis, cough, fever, pharyngitis, bronchiolitis, and diarrhea, and a minority was possibly attributed to palivizumab. The overall hospitalization rate was 7%, the RSV hospitalization rate 2.1%; and no deaths occurred during the study period. 51 The "Second Season Safety Study" was designed to exclude concerns that palivizumab might cause an adverse immune response during a second RSV season. 52 Children up to 2 y of age were selected as either first season study participants with no previous palivizumab exposure or second season participants, who had received palivizumab throughout the previous RSV season. Palivizumab 
Metaanalyses regarding clinical and economic efficacy
A Cochrane review on palivizumab published in 2013 found palivizumab prophylaxis being effective in reducing RSV hospitalization rates in high-risk infants. 53 The cumulative relative reduction was 0.49 (95% confidence interval 0.37 to 0.64) when compared with placebo from 3 randomized controlled trials including 2831 infants. Economic analyses of palivizumab prophylaxis in this review revealed conflicting results with broad variations of incremental cost-effectiveness and/or cost-utility ratio values suggesting that palivizumab either was cost-effective or not cost-effective depending on many variables included in the respective pharmacoeconomic calculation model. 53 Another systematic review including 13 studies revealed palivizumab to be cost-effective for particular subgroups at a threshold of £30,000 per quality-adjusted life-year (QALY). 54 For preterm infants without bronchopulmonary dysplasia or congenital heart disease cost-effectiveness was given for those being 6 weeks of age or less at the onset of the RSV season and having 2 other RSV risk factors and a gestational age of 24 weeks or less. Palivizumab was cost-effective for children with bronchopulmonary dysplasia if they were 6 months of age or less at the onset of the season and had a gestational age of 28 weeks or less. For children with acyanotic or cyanotic congenital heart disease cost-effectiveness was given when they were younger than 6 months of age and had a gestational age of 24 weeks or less. Limitations of this economic analysis included the poor quality of the studies included. Differences existed across studies regarding true and estimated numerical results that were taken into account for analyses (poor-quality inputs) and finally led to considerable variations. 54 A systematic literature review and meta-analysis on RSV associated morbidity and mortality including 10 comparative studies of palivizumab prophylaxis and evaluating more than 15,000 infants reported on an all-cause mortality associated with palivizumab of 0.19% (12 of 6380) compared with 0.53% (33 of 8182) for infants not having received palivizumab prophylaxis over the RSV season (odds ratio, 0.30; 95% confidence interval, 0.17-0.55). 55 Only 5 RSV related deaths were reported. The RSV hospitalization rate was significantly reduced in palivizumab recipients (4.1% vs. 10.4%; odds ratio 0.35; 95% confidence interval 0.25-0.47). 55 
Regulatory issues
In 1998, palivizumab was approved by the Food and Drug Administration (FDA) for RSV prophylaxis of high-risk children in the USA; approval of the European Agency for the Evaluation of Medicinal Products (EMEA) followed in 1999 for Europe. 56 Palivizumab received approval in over 45 countries worldwide in the early 2000s. The main goal of immunoprophylaxis with palivizumab was achieved by significantly reducing RSV hospitalization rates in high-risk infants in North America and Europe. 56 
AAP guidelines over the years
The first guidelines for the use of palivizumab were published by the AAP 57 as a result of the phase III study published in 1998. 48 Palivizumab was mainly recommended for infants and children up to the age of 2 y with bronchopulmonary dysplasia (requiring medical therapy or respiratory support for their disease within 6 months before the second RSV season), and for preterm infants (those born at 28 weeks of gestational age or less up to 12 months and those born at 29 to 32 weeks up to 6 months of age). For those infants of 33 to 35 weeks of gestational age additional risk factors had to be evident including neurologic disease, presence of young siblings, child care attendance, passive tobacco smoke exposure, planned cardiac surgery or difficulties regarding medical support for severe respiratory disease). In 2003 the AAP provided additional guidelines for administering RSV prophylaxis to infants and children with hemodynamically significant congenital heart disease. 58 Palivizumab recommendations were changed for preterm infants of 32 to 35 weeks of gestational age by risk factor stratification (presence of 2 or more risk factors including child care attendance, school-aged siblings, exposure to environmental air pollutants, congenital abnormalities of the airways, or severe neuromuscular disease). In 2009 again guidelines were changed, now reducing the moderate and late preterm infant population to 32 to 34 weeks of gestational age. Additional risk factors required were the presence of either child care attendance or one or more siblings less than 5 y of age. 59 A bulk of largely divergent cost-benefit analyses of palivizumab prophylaxis was published over the last decade. [53] [54] [55] 60 Results varied enormously, as stated shortly above, and the majority of studies did not reveal cost-effectiveness except for subgroups of high-risk infants. Some authors concluded that reducing the costs of palivizumab would lead to broader use of the Mab in high-risk infants.
In 2014 the AAP revised its recommendations completely. 61 The authors stated that palivizumab might be given to preterm infants at 28 weeks of gestational age or less at a maximum of 5 doses during one season. No recommendations for otherwise healthy preterm infants of 29 to 35 weeks of gestational age were provided and unchanged ones for infants with bronchopulmonary dysplasia or congenital heart disease. The committee further could not found clear evidence for the use of palivizumab in infants with anatomic pulmonary abnormalities or neuromuscular disease, Down syndrome, cystic fibrosis, or immunocompromised status. 61 
Ongoing debate regarding palivizumab recommendations
The 2014 recommendations are in contrast to a bulk of literature describing the increased risk of RSV related hospitalizations in these populations; [62] [63] [64] [65] [66] [67] and in disregard to the evidence of prospective studies. 68, 69 The AAP published an additional technical report on their updated guidance for palivizumab prophylaxis. 70 Shortly, the committee provides different and/or alternate data regarding palivizumab pharmacokinetics, regarding the seasonality of RSV circulation, regarding an overall declining incidence of bronchiolitis associated hospitalizations in the USA (that does not apply to other countries), regarding lower RSV mortality rates than previously reported, regarding an only moderate influence on reduced wheezing episodes following palivizumab prophylaxis (even in the presence of significant study findings), regarding questionable benefit for cystic fibrosis or Down syndrome patients, regarding reports on palivizumab resistant RSV isolates from palivizumab recipients, and regarding cost analysis studies (most of them were done with the manufacturers support, and independent studies revealed high costs for a small benefit). This is only to provide information on a still ongoing debate regarding recommendations for palivizumab prophylaxis. Since 20 y palivizumab remains the only licensed tool against RSV in high-risk populations. A further discussion is beyond this review. Some recent publications either provide relevant epidemiological data on different subgroups of high-risk infants regarding RSV hospitalization rates [71] [72] [73] [74] or give some insights in the debate on the new AAP guidelines and its consequences to the reader. [75] [76] [77] [78] [79] Recommendations for palivizumab prophylaxis differ by far from country to country; details are beyond this product review. Since the introduction of palivizumab in to clinical use the discussion concerning the high costs of the product and its incomplete efficacy remains to be a never ending story.
From the manufacturers view palivizumab is licensed for preterm infants of 35 weeks of gestational age and younger with and without bronchopulmonary dysplasia and for infants with hemodynamically significant congenital heart disease according to the above mentioned trials. 44 An Italian consensus conference reviewed the evidence regarding efficacy and safety of palivizumab and its recommendations. 80 The conference members recommended palivizumab prophylaxis comparable to the latest AAP recommendations. Regarding other rare diseases -as discussed above -the conference members referred the task to specialists, who should have to evaluate the seriousness of the disease and to estimate the probability of a serious RSV infection. 80 This seems to be a difficult decision on the base of limited clinical evidence.
At least there raised discussion about the threshold protective serum palivizumab concentration suggesting that 25 to 30 mg/mL derived from the cotton rat model might be enough and about the number of monthly injections needed. Five injections have been given through all the studies and been recommended by the manufacturer, 44 but models suggest that 3 to 4 injections starting at a variable season dependent time point might be enough with cost savings of 20% and without increased RSV hospitalization rates. [81] [82] [83] Recent epidemiologic data In a retrospective sequential 2 time period analysis comparing the rates of RSV hospitalization in patients younger than 2 y of age before and after implementation of the AAP 2014 guidelines on the use of palivizumab the rates did not differ between periods (5.37 versus 5.78 per 1000 children <24 months). 77 This effect was associated with significantly less use of palivizumab (21.7 doses of palivizumab decreased to 10.3 doses per 1000 children <24 months). 77 Very recently, RSV hospitalization rates have been reported that were (1) lower compared with historical reports 2 decades before for preterm infants and those with bronchopulmonary dysplasia, [84] [85] [86] [87] (2) still remarkable regarding infants with congenital heart disease, 88, 89 and (3) interesting regarding other rare diseases. 84, 90, 91 Recommendations to prevent nosocomial RSV infection
The role of palivizumab to prevent nosocomial spread of RSV is unclear as far as it is mainly used in multicomponent control strategies. Nosocomial RSV infection is known to be associated with severe courses of disease and high mortality, especially in case of underlying disease. 92 RSV transmission risk varies by hospital settings and has been reported to range from 6 to 56% (median 28¢5%) in neonatal and/or pediatric settings. 93 Eleven studies used palivizumab as a measure to control nosocomial RSV outbreaks; their study designs lack a control /comparator group, therefor, reported success rates are difficult to interpret. 93 
Palivizumab and motavizumab
A new humanized Mab derived from palivizumab was developed in the early 2000s. 94 Shortly, variants of palivizumab with enhanced in vitro neutralization of RSV were created. Testing of these modified Mabs in cotton rats resulted in an only marginally improvement in neutralization capacity compared with palivizumab. This surprising small effect resulted from unforeseeable broad tissue binding. Further analyses showed that small changes at the affinity binding region markedly improved the non-specific binding to various tissues. The resulting Mab, motavizumab, bound 70-fold better to RSV F than palivizumab; and showed a 20-fold better neutralization result in vitro. Motavizumab reduced pulmonary RSV titers in cotton rats by 100-fold lower levels compared with palivizumab at same concentrations; and highly potent stopped nasal viral replication. 94 Children hospitalized due to RSV LRTI received intravenous motavizumab at either3, 15, or 30 mg/kg or a placebo to test its safety and tolerability and to assess motavizumab concentrations and its immunogenicity 95 Motavizumab significantly reduced viral loads in the upper respiratory tract. No adverse events were associated with motavizumab administrations. 95 In a multinational study including 6635 preterm infants with and without bronchopulmonary dysplasia motavizumab showed a 26% relative reduction of RSV related hospitalizations compared with palivizumab, thus demonstrating non-inferiority. 96 This result of the in vivo performance of motavizumab was a little bit disappointing.
Between April 2006 and May 2006, 260 high-risk infants randomly received either 2 monthly injections of motavizumab followed by 3 injections of palivizumab or 2 times palivizumab followed by 3 times motavizumab or at least solely 5 times motavizumab that resulted in comparable adverse events rates, serum concentrations and presence of antidrug antibodies. 97 Motavizumab and palivizumab proved to be save and well tolerated in 1236 children with hemodynamically significant congenital heart disease up to the age of 2 years; only skin events were more often diagnosed in motavizumab recipients. 98 RSV outpatient medically attended LRTI occurred at similar rates between groups.
Interestingly, motavizumab was tested in term Native American infants up to the age of 6 months (randomized 2:1 placebo-controlled) resulting in an 87% relative reduction of RSV hospitalizations (2% vs. 11%). 99 Adverse events occurred less common in the motavizumab group; but hypersensitivity reactions were more common seen (14.7 vs. 12.3%). No influence was found on wheezing episodes up to 3 y of age. This was an impressive result demonstrating the first use of RSV immunoprophylaxis in term infants. 99 The Antiviral Drugs Advisory Committee of the FDA did not approve motavizumab as requested from the company in 2010. 100 Concerns about safety, allergic reactions, and confusion about the sponsor's decision to show that the agent was non-inferior to palivizumab were the main reasons for the expert panel to vote against approval.
Latest monoclonal antibodies against RSV
Recently, the development of RSV Mab went toward extension of the serum half-life of the Mab. 101 Such a Mab would lead to less frequent dosing and might be a milestone in RSV immunoprophylaxis. This new Mab named motavizumab-YTE was studied in 31 healthy adults who received a single intravenous dose compared with motavizumab at different doses (0.3, 3, 15, or 30 mg/kg) over a 240 d follow-up. 102 The half-life of motavizumab-YTE was 2 to 4 times longer compared with motavizumab as was the clearance lower (71 compared with 86%). Peak concentrations and distribution properties were similar independent from motavizumab dosages. Motavizumab-YTE serum concentrations necessary for RSV neutralization persisted for 240 d compared with 90 d for motavizumab. Safety and presence of antidrug antibodies did not differ between both MAbs. 102 The latest development is REGN-2222, a completely human IgG MAb targeting the F protein. 103 This Mab showed in vitro (in cotton rats) a 36-fold better inhibition of RSV fusion to the cells and a 10-40-fold better reduction of viral loads both in the lung and the upper respiratory tract compared with palivizumab. A phase-I dose escalation study conducted in healthy adults of 18-60 y of age showed a longer half-life associated with low immunogenicity. A phase-III study (www.clinical trials.gov; NCT02325791) including preterm infants of chronological age below 6 months is currently underway. REGN-2222 is administered intramuscularly and is expected to be dosed only one or 2 times over the RSV season. 103 The challenging task of adherence and compliance to palivizumab dosing Palivizumab does not reduce the risk of RSV infection by 100%. As shown by data from the Palivizumab Outcomes Registry 46% of all hospitalizations occur following the first injection, and 29% after the second injection; thereafter rates vary between 4 and 10% at 35-days intervals. 104 Hence, it might have played a role that palivizumab trough serum concentrations were less than 40 mg/mL following the first palivizumab dose in about 33% of the infants; and following their second or third dose up to 14%. 46 Another critical point are the recommended time-intervals between palivizumab injections of 28 to 30 d. 44 Delays in the injection scheme sometimes add to the challenge of adherence to the palivizumab injection scheme. Some outpatient doctors erroneously argue that interim infections with fever are contraindications for palivizumab injections as this is the case for routine vaccine administration. Another reason for compliance problems is missing parental education regarding RSV infection, thorough hand hygiene and practical application of palivizumab prophylaxis. 105 Compliance was significantly improved by a home-based compared with the normal office palivizumab administration regimen (compliance 98% vs. 89%, p < 0.001) resulting in a significant reduction of RSV hospitalizations (0.93% vs. 3.57%, p < 0.001). 106 Nevertheless, this regimen is not realizable and probably not affordable for daily practice. A lot of measures including reminder telephone calls, extensive counseling programs, reminder calendars, and education in the respective native language led to increased compliance, but results rarely were significant. 107 Several studies recommend education of parents on palivizumab prophylaxis, support on transportation, transcultural and language difficulties, and assistance in recognizing severity of RSV disease to improve compliance. In a large review including 10,390 infants identified from disposal records provided by a pharmaceutic company, RSV hospitalization rates were significantly lower in the compliant group (1.4% vs. 3.1%). 107 This data was confirmed by a large study from the Canadian registry of palivizumab reporting that adherence to the monthly injection regimen was significantly associated with a lower incidence of RSV infections. 108 
Commercial issues and product availability
Palivizumab was available as Synagis 50 mg or 100 mg powder and solvent for solution for injection until 2016 (lyophilized palivizumab). Now palivizumab is available as single-dose liquid solution vials at 50 mg per 0.5 ml and 100 mg per 1.0 ml (liquid palivizumab) for intramuscular injection. Two clinical studies compared liquid to lyophilized palivizumab in preterm infants and found comparable safety, efficacy, tolerability, immunogenicity, and pharmacokinetics. 109, 110 Caution should be given in case of moderate and severe thrombocytopenia and coagulation disorders. 44 Anaphylaxis (< 1 case per 100,000 patients) has rarely been reported. In 2002 (Medimmune letter dated November 26, 2002) following experience with 2,000,000 doses palivizumab administrations 2 cases of anaphylaxis had been reported. Adverse effects commonly found were URTI, otitis media, fever, rhinitis, hernia, and elevations of serum AST. In the former trial, 48 infants had received routine childhood vaccines, influenza vaccine, bronchodilators or corticosteroids during the study period in similar rates regarding study groups. Adverse reactions were not found to be increased. Thus, active immunization does not seem to interfere with palivizumab. There is no knowledge regarding carcinogenesis, mutagenesis and reproductive toxicity and no further experience of its prophylactic use in adults or pregnancy. 44, 111 A review of deaths among children below 2 y of age having received palivizumab revealed 133 cases over a 4-year study period (1998 -2001) . 112 The median age of the cohort was 5 months, and 54% were male. Most of the deaths were associated with congenital anomalies in 38% (singular anomalies were reported in 64%, multiple anomalies in 44%) or with respiratory infections in 23%. Palivizumab was not found to further elevate the risk of death. 112 The manufacturer further states, that palivizumab is not licensed for the treatment of RSV disease. 44 A phase I/II study using different palivizumab single intravenous doses for the treatment of RSV disease failed to demonstrate clinical benefits. 113 Hence, palivizumab is no treatment option for established RSV disease.
Conclusions
Palivizumab is a safe and well tolerated Mab for the prophylactic use to reduce the risk of severe RSV infection needing hospitalization in high-risk infants; i.e. including those born preterm ( 35 weeks of gestational age up to the chronological age of 12 months), and those with bronchopulmonary dysplasia and hemodynamically significant congenital heart disease (up to the chronological age of 24 months). Predominantly palivizumab is given intramuscularly at 5 doses of 15 mg/kg over the first RSV season; in cases needing treatment of their underlying disease (bronchopulmonary dysplasia, congenital heart disease) prophylaxis might be given over a second RSV season, and in selected cases of clinical rare pathologic conditions (cases with lung hypoplasia, neuromuscular impairment, tracheostomy, etc.) palivizumab is given at the decision of the specialist. Since nearly all RSV related deaths (99%) occur in developing, resource poor countries without the possibility of palivizumab prophylaxis due to the high costs of the product, palivizumab has limited potential to reduce the global burden of RSV disease. 114 As far as a vaccine still is not in sight and no simply and effective antiviral treatment of RSV exists, prophylactic palivizumab administrations remain the only tool in the prevention of severe RSV infection in high-risk infants. Long lasting Mabs like motavizumab-YTE are likely to replace palivizumab in the near future until a successful vaccine is on the market.
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